Quantitative Research of 11C-CFT and 18F-FDG PET in Parkinson's Disease: A Pilot Study With NeuroQ Software
Quantitative Research of 11C-CFT and 18F-FDG PET in Parkinson's Disease: A Pilot Study With NeuroQ Software
复制标题
C-11-CFT 和 F-18-FDG PET 在帕金森病中的定量研究：使用 NeuroQ 软件进行的初步研究
DOI：
10.3389/fnins.2019.00299
复制
发表时间：
2019-04-05
影响因子：
4.3
通讯作者：
Lan, Xiaoli
中科院分区：
文献类型：
--
作者：
Sun, Xun;Liu, Fang;Lan, Xiaoli
多巴胺转运蛋白（DAT）和糖代谢显像在帕金森病（PD）的诊断中已得到应用。我们通过分析C-11-2 β-甲氧羰基-3 β-（4-氟苯基）托烷（C-11-CFT）和F-18-FDG PET/CT，探讨NeuroQ软件评估PD的可能性。回顾性分析38例帕金森综合征患者（PD 20例，多系统萎缩（MSA）10例，特发性震颤（ET）8例）的脑C-11-CFT和F-18-FDG PET/CT，并与11例正常对照者（NC）的PET/CT进行比较。根据Hoehn-Yahr（H&Y）量表将PD患者分为轻度和中重度。采用手工方法和NeuroQ软件计算尾状核（CN）和壳核（Pu）的C-11-CFT摄取，并将其与小脑（CN/Cb和Pu/Cb）标准化，比较其诊断性能。同时用NeuroQ获得特定区域的F-18-FDG摄取，并评价其增强效果以用于鉴别诊断。对于CN（r（2）= 0.680）和Pu（r（2）= 0.770）的C-11-CFT摄取，手动方法和NeuroQ方法之间存在显著一致性。与NC和ET患者相比，PD和MSA患者中CN和Pu的C-11-CFT摄取显著降低。区分PD和NC的CN/Cb和Pu/Cb的截断值分别为1.71和2.20。PD和MSA之间的摄取率无差异。MSA组脑桥和小脑的F-18-FDG摄取明显减少。当结合C-11-CFT摄取分析时，它在区分PD和MSA方面具有高度准确性。与NC组相比，轻度PD组的Pu/Cb显著降低（1.92 +/- 0.33 vs. 2.82 +/- 0.43）;然而，直到中重度PD，CN/Cb未观察到统计学显著降低（1.43 +/- 0.11 vs. 2.23 +/- 0.36）。在早期不对称PD中，在有症状侧和无症状侧之间Pu/Cb存在统计学显著差异（2.17 +/- 0.30 vs. 1.95 +/- 0.22）。NeuroQ软件可对C-11-CFT和F-18-FDG PET进行定量分析，为PD的诊断和严重程度评估提供了准确的方法。
Dopamine transporter (DAT) and glucose metabolism imaging have been applied in the diagnosis of Parkinson's disease (PD). We explored the possibility of evaluating for PD with NeuroQ software by analyzing C-11-2 beta-carbomethoxy-3 beta-(4-fluorophenyl) tropane (C-11-CFT) and F-18-FDG PET/CT. We retrospectively analyzed brain C-11-CFT and F-18-FDG PET/CT of 38 patients with parkinsonism, including 20 with PD, 10 with multiple system atrophy (MSA) and 8 with essential tremor (ET), and compared them with the PET/CT of 11 normal healthy controls (NC). PD patients were divided into mild and moderate-severe grade according to the Hoehn-Yahr (H&Y) scale. The C-11-CFT uptake in the caudate nuclei (CN) and putamen (Pu) normalized with cerebellum (CN/Cb and Pu/Cb) were obtained with a manual method and NeuroQ software, and their diagnostic performance was compared. F-18-FDG uptake of specific regions was also obtained with NeuroQ, and the enhancement effect for the differential diagnosis was evaluated. There was significant agreement between the manual method and the NeuroQ method for C-11-CFT uptake by CN (r(2) = 0.680) and Pu (r(2) = 0.770). C-11-CFT uptake by CN and Pu in PD and MSA patients was significantly lower compared to NC and ET patients. The cutoffs of CN/Cb and Pu/Cb for the distinction between PD and NC were 1.71 and 2.20, respectively. No difference in uptake ratios occurred between PD and MSA. F-18-FDG uptake by the pons and cerebellum in the MSA group was markedly decreased. It was highly accurate in distinguishing between PD and MSA when combined with analysis of C-11-CFT uptake. Pu/Cb decreased significantly in mild grade PD compared to NC group (1.92 +/- 0.33 vs. 2.82 +/- 0.43); however no statistically significant decrease in CN/Cb was observed until moderate-severe grade PD (1.43 +/- 0.11 vs. 2.23 +/- 0.36). In early asymmetric PD, a statistically significant difference could be seen with Pu/Cb between the symptomatic and asymptomatic side (2.17 +/- 0.30 vs. 1.95 +/- 0.22). C-11-CFT and F-18-FDG PET can be analyzed quantitatively with NeuroQ software, which provides an accurate method for the diagnosis and severity evaluation of PD.